-
Understanding sexual pain remains limited. with multiple etiologies and lack of evidence-based outcomes research, future investigations should focus on evaluating the intimacy of the couple, the partner relationship, and biomedical sources of pain such as the pelvic floor muscles.
-
-
The authors performed a descriptive analysis of all cases of desquamative inflammatory vaginitis (DIV), defined as symptomatic vaginitis (discharge, dyspareunia, pruritus, burning, or irritation) associated with vaginal inflammation (such as focal or linear erosions), a vaginal pH higher than 4.5, and saline microscopy showing an increase in parabasal and inflammatory cells in the absence of an infectious etiology (such as trichomonas, candida, or bacterial vaginosis).
-
In this issue: Two new drugs for treatment of hepatitis C; NSAIDs and myocardial infarction risk; AIM-HIGH clinical trial stopped; and FDA actions.
-
Results of a new study indicate patients who have tested positive for herpes simplex virus type 2 (HSV-2) but don't have symptoms or genital lesions still experience virus shedding during subclinical episodes.
-
The Food and Drug Administration (FDA) and the Federal Trade Commission have issued a joint call to remove products from the market that make unproven claims to treat, cure, and prevent sexually transmitted diseases (STDs).
-
Investigators have discontinued the FEM-PrEP study of oral emtricitabine and tenofovir disoproxil fumarate (Truvada, Gilead Sciences, Foster City, CA) to prevent HIV infection in women in Africa after interim results indicated the research would be unlikely to prove effectiveness in the study population.
-
Results of two case-control studies indicate that women without risk factors for venous thromboembolism (VTE) who use oral contraceptives (OCs) containing drospirenone have an increased risk for nonfatal VTE compared with those who use levonorgestrel OCs.
-
A just-published study indicates that many providers are failing to counsel women on the availability of emergency contraception (EC).
-
Add another human papillomavirus (HPV) test to the clinical arsenal. The Food and Drug Administration (FDA) has approved the Roche cobas HPV Test.
